Home » Stocks » NWBO

Northwest Biotherapeutics, Inc. (NWBO)

Stock Price: $1.71 USD 0.21 (14.00%)
Updated May 14, 2021 3:59 PM EDT - Market closed
Market Cap 1.44B
Revenue (ttm) 1.29M
Net Income (ttm) -529.82M
Shares Out 725.13M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $1.71
Previous Close $1.50
Change ($) 0.21
Change (%) 14.00%
Day's Open 1.51
Day's Range 1.50 - 1.74
Day's Volume 4,825,736
52-Week Range 0.18 - 2.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ann...

4 days ago - PRNewsWire

BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...

1 month ago - PRNewsWire

NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.

4 months ago - Seeking Alpha

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Other stocks mentioned: NVCR
6 months ago - The Motley Fool

With Data Lock just announced, Top Line Date is imminent.

7 months ago - Seeking Alpha

About NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The compa... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Linda Powers
Employees
19
Stock Exchange
OTCMKTS
Ticker Symbol
NWBO
Full Company Profile

Financial Performance

In 2020, NWBO's revenue was $1.29 million, a decrease of -46.43% compared to the previous year's $2.41 million. Losses were -$529.82 million, 2,445.7% more than in 2019.

Financial Statements